SCHEMBL623990

SCHEMBL623990

CC(C)COc1cc(N2CCN(C(=O)CNC(=O)c3ccc(OCC(F)(F)F)nc3)CC2)ncn1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.43
SCD O00767 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
CYP2J2 P51589 1/20 0.42
ACACB O00763 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.39
SCN9A Q15858 5/20 0.39
KCNH2 Q12809 2/20 0.39
SCN5A Q14524 2/20 0.39
DGAT1 O75907 2/20 0.39
TRPV1 Q8NER1 1/20 0.38
HDAC1 Q13547 1/20 0.38
TIPARP Q7Z3E1 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
SCN10A Q9Y5Y9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL624486 0.85 THRA (0.45) KDM4ELMNAMAPT
SCHEMBL15006743 0.83 KMT2A (0.50) KDM4ELMNAMAPT
SCHEMBL12473598 0.79 LRRK2 (0.38) CYP2C19ACACBKDM4E
SCHEMBL623276 0.76 KDM4E (0.46) KDM4E
SCHEMBL624480 0.76 P2RY12 (0.44) KDM4ELMNA
SCHEMBL624371 0.75 KCNK3 (0.44) SCDACACBL3MBTL1SCN9A
SCHEMBL624206 0.73 NPC1 (0.45) L3MBTL1KDM4ELMNA
SCHEMBL624194 0.73 IDE (0.44) ACACBLMNAMAPT
SCHEMBL623187 0.73 TP53 (0.39) CYP2C9CYP2C19HDAC1HDAC6KDM4E
SCHEMBL624044 0.72 CKS1B (0.41) CYP2C19ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G EPHX2 3564/4885SCD 2066/4885CYP2C9 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.